Perspectum
Medical AI · Medical Imaging Systems
$8.3Mraised in 26 rounds
A-ratedvisa sponsor licence, United Kingdom
10stories in the press
2012founded
Visa sponsorship
A-rated
Sponsor licence
Skilled Worker
Visa route
0
Open roles in United Kingdom
In the register as Perspectum Ltd, Oxford, Oxon
Other sponsors in the same field
HeartFlow 
Hypervision Surgical 
Brainomix
Ultromics
Alert me
UK Home Office · checked Nov 7, 2026 · Visa details by country
Financials
Total raised
$8.3M
Latest round
Grant
Funding rounds
26
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Grant | 2026 | $1.6M | Details |
| Venture - Series Unknown | 2021 | — | Details |
| Grant | 2021 | — | Details |
| Grant | 2020 | $119k | Details |
| Grant | 2020 | $533k | Details |
| Grant | 2019 | — | Details |
| Grant | 2019 | $145k | Details |
| Grant | 2019 | $452k | Details |
| Venture - Series Unknown | 2019 | — | Details |
| Grant | 2019 | $162k | Details |
| Grant | 2019 | — | Details |
| Grant | 2019 | — | Details |
| Grant | 2019 | $154k | Details |
| Venture - Series Unknown | 2018 | — | Details |
| Venture - Series Unknown | 2018 | — | Details |
| Venture - Series Unknown | 2017 | — | Details |
| Grant | 2017 | $278k | Details |
| Grant | 2017 | $295k | Details |
| Grant | 2017 | $667k | Details |
| Venture - Series Unknown | 2016 | — | Details |
| Grant | 2016 | $3.7M | Details |
| Grant | 2016 | $170k | Details |
| Venture - Series Unknown | 2015 | — | Details |
| Grant | 2015 | $54k | Details |
| Venture - Series Unknown | 2014 | — | Details |
| Venture - Series Unknown | 2013 | — | Details |
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
Oxford Science EnterprisesVia a fund
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
Singapore Institute of Advanced Medicine Holdings (SAM) Partners with Perspectum to Expand CoverScan Multi-Organ Health Assessment in SingaporeProgram for the expansion of quantitative, non-invasive MRI assessment of multiple organs to preventive health services in Singapore
OXFORD, U.K. and SINGAPORE - AUGUST 06, 2026 - Perspectum, a precision health company that delivers non-invasive solutions to accelerate drug development and improve patient outcomes in metabolic disease, today announced with Singapore Institute of Advanc
Read more
Report
Sir Mike Brady Elected as an International Member of the National Academy of Engineering
We are proud to share that our co-founder, Sir Michael Brady, has been elected to the National Academy of Engineering (NAE).Election to the NAE is among the highest professional distinctions awarded to an engineer. Michael has been recognised for his cont
Read more
Report
Perspectum Announces Executive Leadership Changes
Dr. Rajarshi Banerjee is no longer with Perspectum. The Board has appointed the Company's Chief Operating Officer, Dr. Rexford Newbould, as Interim Chief Executive Officer, alongside Dr. Mike Rosenblatt who will assume the role of Executive Chair. The Boa
Read more
Report
Perspectum and Avant Santé announce strategic partnership to strengthen quantitative imaging for metabolic and liver research in Mexico and Latin America
Boston, MA and Monterrey, Mexico - 17 December 2025. Perspectum, a global medical technology company advancing quantitative imaging for metabolic, liver and multi-organ health, today announced a strategic partnership with Avant Santé, a patient-centric co
Read more
Report
Perspectum and InHealth announce national diagnostics partnership to boost Oxford CDC capacity and widen access to advanced MRI across the UK
Perspectum and InHealth have announced a new national diagnostics partnership that will significantly expand access to advanced MRI and increase capacity at the Oxford Community Diagnostic Centre (CDC). The Oxford CDC, one of NHS England's leading sites,
Read more
Report
New analysis shows corrected T1 (cT1) is the most appropriate diagnosis and monitoring tool for widespread adoption of resmetirom treatment in the United States
WASHINGTON, D.C. - SEPTEMBER 03, 2025 - (BUSINESS WIRE) - Newly published economic modeling concludes that Perspectum's proprietary biomarker cT1 may help US Veterans Administration (VA) health care enrollees gain better access and treatment for MASH (met
Read more
Report
UK Biobank Completes World's Largest Human Imaging Study
UK Biobank has marked the successful completion of the world's largest human imaging study, with over 60,000 participants scanned as part of its landmark research programme. The celebration highlighted the power of large-scale imaging for advancing health
Read more
Report
Marea Therapeutics Publishes Phase 2 Trial Results in The Lancet
Perspectum is proud to see one of our commercial collaborations reach a major milestone, with results from an early-phase clinical trial now published in The Lancet. This study, led by Marea Therapeutics, evaluated the safety and efficacy of MAR001, a nov
Read more
Report
Major Study Shows Liver Health Measured with cT1 Predicts Clinical Outcomes
WASHINGTON - Nature Medicine today published a study showing that Perspectum's iron corrected T1, or cT1, predicts liver-related and cardiac outcomes, including morbidity. Liver disease is a modifiable cardiac risk factor, and this study confirmed that it
Read more
Report
New Multinational Study Shows MRI is Cost-Effective in the Diagnosis and Management of Steatotic Liver Disease
WASHINGTON, D.C. - MARCH 18, 2025 - (BUSINESS WIRE) - Perspectum today released the results of a multinational study showing that LiverMultiScan can reduce liver biopsies, lead to fewer specialist consultations, and improve the rate of diagnosis for patie
Read more
Report
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Oxford
United Kingdom
HQ
Address
5520 John Smith Drive , Oxford, OX4 2LL